Evaluating PET/CT for SSTR-related diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of 68Ga/18F-TATE/JR11/LM3 positron emission tomography/computed tomography (PET/CT) in diagnosing primary and metastatic lesions in patients with SSTR-related diseases. Participants, who are adults with suspected or diagnosed malignant tumors, undergo PET/CT scans to assess the uptake of the imaging agent in their lesions. The study aims to calculate various diagnostic metrics, including sensitivity and specificity, to determine the accuracy of this imaging technique in clinical settings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled SSTR PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria:

\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Where it's running

• The First Affiliated Hospital of University of Science and Technology of China
  Hefei, Anhui, China Recruiting
• The Affiliated Hospital of Qingdao University
  Qingdao, Shandong, China Recruiting
• Tianjin Medical University General Hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Study coordinator: Haonan Yu, MD
• Email: dreamadam@126.com
• Phone: +8613821000597

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating PSMA PET/CT Imaging for Prostate Cancer Patients

  This study is testing a special type of imaging called PSMA PET/CT to see if it can help find cancer in adults who have or might have prostate cancer.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT06690970

• Imaging CXCR4-related diseases using PET/CT

  This study is testing a new type of imaging to see if it can better identify and track diseases related to CXCR4 in patients.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT06690736

• Evaluating FAPI PET/CT for Diagnosing FAP-Related Diseases

  This study is testing if a special type of scan can help find cancer in adults who have or might have tumors related to FAP.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT06688071

• 68Ga-FAPI PET/CT imaging to detect primary and metastatic cancer lesions

  This study tests whether 68Ga-DOTA/NOTA-FAPI-04 PET/CT can help find primary tumors and metastases in adults with various cancers.

  Recruiting Early Phase 1 First Affiliated Hospital of Fujian Medical University · Fuzhou, Fujian · NCT04499365

• Comparing two types of PET scans for cancer diagnosis

  This study is testing whether a new type of PET scan can find cancer better than the standard scan in patients who have or might have tumors.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT04416165

• PD-L1 PET/CT to see primary and metastatic PD-L1-related lesions in adults

  This study tests whether 68Ga/18F-PD-L1 PET/CT can help detect primary and metastatic PD-L1-related tumors in adults.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT07618936

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.